Full identifier: http://www.w3.org/2000/01/rdf-schema#sentence
| Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
|---|---|---|---|---|---|---|
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
In vitro dexamethasone inhibited tissue inflammation via macrophages MerTK function.
|
Eva Zegelaar
|
2021-07-25T21:48:07.976Z
|
||
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
Simulations suggest that linoleate and dexamethasone stabilize the locked spike conformation, thus reducing the opportunity for ACE2 interaction.
|
Eva Zegelaar
|
2021-07-25T21:48:04.785Z
|
||
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
Simulations suggest that linoleate and dexamethasone stabilize the locked spike conformation, thus reducing the opportunity for ACE2 interaction.
|
Eva Zegelaar
|
2021-07-25T21:48:03.393Z
|
||
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
A regimen of hydroxychloroquine, azithromycin, and dexamethasone was initiated on admission in 3 severe cases of COVID-19 pneumonia in cruise ship employees who were admitted to the ICU and responded to supportive mechanical ventilation and pulmonary hygiene management.
|
Eva Zegelaar
|
2021-07-25T21:48:01.913Z
|
||
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients.
|
Eva Zegelaar
|
2021-07-25T21:48:00.422Z
|
||
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
|
Eva Zegelaar
|
2021-07-25T21:47:58.637Z
|
||
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity.
|
Eva Zegelaar
|
2021-07-25T21:47:56.729Z
|
||
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity.
|
Eva Zegelaar
|
2021-07-25T21:47:55.281Z
|
||
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity.
|
Eva Zegelaar
|
2021-07-25T21:47:53.804Z
|
||
|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
sentence
|
Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy.
|
Eva Zegelaar
|
2021-07-25T21:47:52.320Z
|
||